We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $7.84, marking a -1.26% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.46%. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 0.64%.
Shares of the biotechnology company witnessed a loss of 21.93% over the previous month, trailing the performance of the Medical sector with its loss of 4.9% and the S&P 500's loss of 3.04%.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. The company is forecasted to report an EPS of -$0.43, showcasing a 26.47% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.36 million, indicating a 10.1% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.63 per share and a revenue of $45.75 million, representing changes of -3.16% and +2.63%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Recursion Pharmaceuticals boasts a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 93, placing it within the top 37% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $7.84, marking a -1.26% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.46%. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 0.64%.
Shares of the biotechnology company witnessed a loss of 21.93% over the previous month, trailing the performance of the Medical sector with its loss of 4.9% and the S&P 500's loss of 3.04%.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. The company is forecasted to report an EPS of -$0.43, showcasing a 26.47% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.36 million, indicating a 10.1% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.63 per share and a revenue of $45.75 million, representing changes of -3.16% and +2.63%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Recursion Pharmaceuticals boasts a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 93, placing it within the top 37% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.